Applying convergent immunity to innovative vaccines targeting Staphylococcus aureus

Frontiers in Immunology

Volumn 5, Issue SEP, 2014, Pages

  Yeaman, Michael R ^a,b,c   Filler, Scott G ^a,b,c   Schmidt, Clint S ^d   Ibrahim, Ashraf S ^a,b,c   Edwards, John E ^a,b,c   Hennessey, John P ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARBOR UCLA MEDICAL CENTER   (United States)

^c St John's Cardiovascular Research Center   (United States)

^d NovaDigm Therapeutics Inc   (United States)

Author keywords

Als3; Convergent antigen; Convergent immunity; NDV 3; Staphylococcus aureus; Vaccines

Indexed keywords

ALPHA HEMOLYSIN; ALPHA TOXIN; APHYLOCOCCUS ENTEROTOXIN B; BACTERIAL ANTIGEN; BACTERIAL VACCINE; COLLAGEN BINDING PROTEIN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C8; DIPHTHERIA TOXOID CRM197; EPITOPE; FUNGUS ANTIGEN; GSK2392; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; LIVE VACCINE; PANTON VALENTINE LEUKOCIDIN; PNEUMOCOCCUS VACCINE; RECOMBINANT ANTIGEN; RECOMBINANT PROTEIN; SA3AG; SA4AG; STAPHYLOCOCCUS VACCINE; STEBVAX; TOXOID; UNCLASSIFIED DRUG; VACCINE; VIRUS VACCINE;

ANTIGEN RECOGNITION; BACTEREMIA; BACTERIAL COLONIZATION; CANDIDA ALBICANS; CLOSTRIDIUM TETANI; CONVERGENT IMMUNITY; CORYNEBACTERIUM DIPHTHERIAE; CROSS PROTECTION; HEMODIALYSIS; HOST RESISTANCE; HUMAN; HUMORAL IMMUNITY; IMMUNITY; IMMUNOREGULATION; IMMUNOTHERAPY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIOME; MURINAE; NEUTROPHIL; NONHUMAN; OPPORTUNISTIC INFECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; PROTEIN PROCESSING; PSEUDOMONAS AERUGINOSA; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; VACCINATION;

EID: 84919421629     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00463     Document Type: Review

References (159)

1. David MZ, Daum RS. Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. Clin Microbiol Rev (2010) 23(3):616-87. doi: 10.1128/CMR.00081-09
2. Gunderson CG, Martinello RA. A systematic review of bacteremias in cellulitis and erysipelas. J Infect (2012) 64(2):148-55. doi:10.1016/j.jinf.2011.11.004
3. DeLeo FR, Otto M, Kreiswirth BN, Chambers HF. Community-associated methicillin-resistant Staphylococcus aureus. Lancet (2010) 375(9725):1557-68. doi:10.1016/S0140-6736(09)61999-1
4. Geria AN, Schwartz RA. Impetigo update: new challenges in the era of methicillin resistance. Cutis (2010) 85(2):65-70.
5. Karamatsu ML, Thorp AW, Brown L. Changes in community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections presenting to the pediatric emergency department: comparing 2003 to 2008. Pediatr Emerg Care (2012) 28(2):131-5. doi:10.1097/PEC.0b013e318243fa36
6. Hersh AL, Chambers HF, Maselli JH, Gonzales R. National trends in ambulatory visits and antibiotic prescribing for skin and soft-tissue infections. Arch Intern Med (2008) 168(14):1585-91. doi:10.1001/archinte.168.14.1585
7. Chambers HF. Community-associated MRSA - resistance and virulence converge. N Engl J Med (2005) 352(14):1485-7. doi:10.1056/NEJMe058023
8. Dantes R, Mu Y, Belflower R, Aragon D, Dumyati G, Harrison LH, et al. National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011. JAMA Intern Med (2013) 173(21):1970-8. doi:10.1001/jamainternmed.2013.10423
9. Tattevin P, Schwartz BS, Graber CJ, Volinski J, Bhukhen A, Bhukhen A, et al. Concurrent epidemics of skin and soft tissue infection and bloodstream infection due to community-associated methicillin-resistant Staphylococcus aureus. Clin Infect Dis (2012) 55(6):781-8. doi:10.1093/cid/cis527
10. Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA (2007) 298(15):1763-71. doi:10.1001/jama.298.15.1763
11. Song X, Cogen J, Singh N. Incidence of methicillin-resistant Staphylococcus aureus infection in a children's hospital in the Washington metropolitan area of the United States, 2003-2010. Emerg Microbes Infect (2013) 2(10):e69. doi:10.1038/emi.2013.69
12. Chambers HF, DeLeo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol (2009) 7:629-41. doi:10.1038/nrmicro2200
13. Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother (2010) 65(Suppl 3):iii35-44. doi:10.1093/jac/dkq302
14. Iwamoto M, Mu Y, Lynfield R, Bulens SN, Nadle J, Aragon D, et al. Trends in invasive methicillin-resistant Staphylococcus aureus infections. Pediatrics (2013) 132(4):e817-24. doi:10.1542/peds.2013-1112
15. Catry B, Latour K, Jans B, Vandendriessche S, Preal R, Mertens K, et al. Risk factors for methicillin resistant Staphylococcus aureus: a multi-laboratory study. PLoS One (2014) 9(2):e89579. doi:10.1371/journal.pone.0089579
16. Jiménez JN, Ocampo AM, Vanegas JM, Rodriguez EA, Mediavilla JR, Chen L, et al. A comparison of methicillin-resistant and methicillin-susceptible Staphylococcus aureus reveals no clinical and epidemiological but molecular differences. Int J Med Microbiol (2013) 303(2):76-83. doi:10.1016/j.ijmm.2012.12.003
17. Stenehjem E, Rimland D. MRSA nasal colonization burden and risk of MRSA infection. Am J Infect Control (2013) 41(5):405-10. doi:10.1016/j.ajic.2012.07.017
18. Quezada SM, Steinberger EK, Cross RK. Association of age at diagnosis and Crohn's disease phenotype. Age Ageing (2013) 42(1):102-6. doi:10.1093/ageing/afs107
19. Duffy J, Dumyati G, Bulens S, Namburi S, Gellert A, Fridkin SK, et al. Community-onset invasive methicillin-resistant Staphylococcus aureus infections following hospital discharge. Am J Infect Control (2013) 41(9):782-6. doi:10.1016/j.ajic.2012.10.020
20. Datta R, Shah A, Huang SS, Cui E, Nguyen V, Welbourne SJ, et al. High nasal burden of methicillin-resistant Staphylococcus aureus increases risk of invasive disease. J Clin Microbiol (2014) 52(1):312-4. doi:10.1128/JCM.01606-13
21. Suresh R, Mosser DM. Pattern recognition receptors in innate immunity, host defense, and immunopathology. Adv Physiol Educ (2013) 37(4):284-91. doi:10.1152/advan.00058.2013
22. Zhong Y, Kinio A, Saleh M. Functions of NOD-like receptors in human diseases. Front Immunol (2013) 4:333. doi:10.3389/fimmu.2013.00333
23. Bauer S, Muller T, Hamm S. Pattern recognition by toll-like receptors. Adv Exp Med Biol (2009) 653:15-34. doi:10.1007/978-1-4419-0901-5_2
24. Yeaman MR. Platelets: at the nexus of antimicrobial defence. Nat Rev Microbiol (2014) 12(6):426-37. doi:10.1038/nrmicro3269
25. Nestle FO, Di Meglio P, Qin JZ, Nickoloff BJ. Skin immune sentinels in health and disease. Nat Rev Immunol (2009) 9(10):679-91. doi:10.1038/nri2622
26. Kupper TS, Fuhlbrigge RC. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol (2004) 4(3):211-22. doi:10.1038/nri1310
27. Renner ED, Rylaarsdam S, Anover-Sombke S, Rack AL, Reichenbach J, Carey JC, et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J Allergy Clin Immunol (2008) 122(1):181-7. doi:10.1016/j.jaci.2008.04.037
28. Horváth R, Rožková D, Laštovicka J, Poloccková A, Sedlácek P, Sedivá A, et al. Expansion of T helper type 17 lymphocytes in patients with chronic granulomatous disease. Clin Exp Immunol (2011) 166(1):26-33. doi:10.1111/j.1365-2249.2011.04449.x
29. de Luca A, Smeekens SP, Casagrande A, Iannitti R, Conway KL, Gresnigt MS, et al. IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans. Proc Natl Acad Sci U S A (2014) 111(9):3526-31. doi:10.1073/pnas.1322831111
30. Miller LS, Pietras EM, Uricchio LH, Hirano K, Rao S, Lin H, et al. Inflammasome-mediated production of IL-1beta is required for neutrophil recruitment against Staphylococcus aureus in vivo. J Immunol (2007) 179(10):6933-42. doi:10.4049/jimmunol.179.10.6933
31. Miller LS, Cho JS. Immunity against Staphylococcus aureus cutaneous infections. Nat Rev Immunol (2011) 11(8):505-18. doi:10.1038/nri3010
32. Greenberg JA, David MZ, Hall JB, Kress JP. Immune dysfunction prior to Staphylococcus aureus bacteremia is a determinant of long-term mortality. PLoS One (2014) 9(2):e88197. doi:10.1371/journal.pone.0088197
33. Metzger DW, Sun K. Immune dysfunction and bacterial coinfections following influenza. J Immunol (2013) 191(5):2047-52. doi:10.4049/jimmunol.1301152
34. Cho JS, Pietras EM, Garcia NC, Ramos RI, Farzam DM, Monroe HR, et al. IL-17 is essential for host defense against cutaneous Staphylococcus aureus infection in mice. J Clin Invest (2010) 120(5):1762-73. doi:10.1172/JCI40891
35. Murphy AG, O'Keeffe KM, Lalor SJ, Maher BM, Mills KH, McLoughlin RM. Staphylococcus aureus infection of mice expands a population of memory gammadelta T cells that are protective against subsequent infection. J Immunol (2014) 192(8):3697-708. doi:10.4049/jimmunol.1303420
36. Krishna S, Miller LS. Host-pathogen interactions between the skin and Staphylococcus aureus. Curr Opin Microbiol (2012) 15(1):28-35. doi:10.1016/j.mib.2011.11.003
37. Bergstresser PR, Tigelaar RE, Dees JH, Streilein JW. Thy-1 antigen-bearing dendritic cells populate murine epidermis. J Invest Dermatol (1983) 81(3):286-8. doi:10.1111/1523-1747.ep12518332
38. McLoughlin RM, Solinga RM, Rich J, Zaleski KJ, Cocchiaro JL, Risley A, et al. CD4+ T cells and CXC chemokines modulate the pathogenesis of Staphylococcus aureus wound infections. Proc Natl Acad Sci U S A (2006) 103(27):10408-13. doi:10.1073/pnas.0508961103
39. Mölne L, Corthay A, Holmdahl R, Tarkowski A. Role of gamma/delta T cell receptor-expressing lymphocytes in cutaneous infection caused by Staphylococcus aureus. Clin Exp Immunol (2003) 132(2):209-15. doi:10.1046/j.1365-2249.2003.02151.x
40. Ishigame H, Kakuta S, Nagai T, Kadoki M, Nambu A, Komiyama Y, et al. Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses. Immunity (2009) 30(1):108-19. doi:10.1016/j.immuni.2008.11.009
41. Spellberg B, Ibrahim AS, Yeaman MR, Lin L, Fu Y, Avanesian V, et al. The antifungal vaccine derived from the recombinant N terminus of Als3p protects mice against the bacterium Staphylococcus aureus. Infect Immun (2008) 76(10):4574-80. doi:10.1128/IAI.00700-08
42. Cho JS, Zussman J, Donegan NP, Ramos RI, Garcia NC, Uslan DZ, et al. Noninvasive in vivo imaging to evaluate immune responses and antimicrobial therapy against Staphylococcus aureus and USA300 MRSA skin infections. J Invest Dermatol (2011) 131(4):907-15. doi:10.1038/jid.2010.417
43. Montgomery CP, Daniels M, Zhao F, Alegre ML, Chong AS, Daum RS. Protective immunity against recurrent Staphylococcus aureus skin infection requires antibody and interleukin-17A. Infect Immun (2014) 82(5):2125-34. doi:10.1128/IAI.01491-14
44. Zeng WP. "All things considered": transcriptional regulation of T helper type 2 cell differentiation from precursor to effector activation. Immunology (2013) 140(1):31-8. doi:10.1111/imm.12121
45. Conlan S, Kong HH, Segre JA. Species-level analysis of DNA sequence data from the NIH Human Microbiome Project. PLoS One (2012) 7(10):e47075. doi:10.1371/journal.pone.0047075
46. Fischer CL, Drake DR, Dawson DV, Blanchette DR, Brogden KA, Wertz PW. Antibacterial activity of sphingoid bases and fatty acids against Gram-positive and Gram-negative bacteria. Antimicrob Agents Chemother (2012) 56(3):1157-61. doi:10.1128/AAC.05151-11
47. Wille JJ, Kydonieus A. Palmitoleic acid isomer (C16:1delta6) in human skin sebum is effective against gram-positive bacteria. Skin Pharmacol Appl Skin Physiol (2003) 16(3):176-87. doi:10.1159/000069757
48. Yount NY, Yeaman MR. Emerging themes and therapeutic prospects for anti-infective peptides. Annu Rev Pharmacol Toxicol (2012) 52:337-60. doi:10.1146/annurev-pharmtox-010611-134535
49. Yeaman MR, Yount NY. Unifying themes in host defence effector polypeptides. Nat Rev Microbiol (2007) 5(9):727-40. doi:10.1038/nrmicro1744
50. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacol Rev (2003) 55(1):27-55. doi:10.1124/pr.55.1.2
51. Korting HC, Schöllmann C, Stauss-Grabo M, Schäfer-Korting M. Antimicrobial peptides and skin: a paradigm of translational medicine. Skin Pharmacol Physiol (2012) 25(6):323-34. doi:10.1159/000341990
52. Dawson MJ, Scott RW. New horizons for host defense peptides and lantibiotics. Curr Opin Pharmacol (2012) 12(5):545-50. doi:10.1016/j.coph.2012.06.006
53. Thomsen IP, Dumont AL, James DB, Yoong P, Saville BR, Soper N, et al. Children with invasive Staphylococcus aureus disease exhibit a potently neutralizing antibody response to the cytotoxin LukAB. Infect Immun (2014) 82(3):1234-42. doi:10.1128/IAI.01558-13
54. Barnett LG, Simkins HM, Barnett BE, Korn LL, Johnson AL, Wherry EJ, et al. B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation. J Immunol (2014) 192(8):3607-17. doi:10.4049/jimmunol.1301284
55. Harvey BP, Raycroft MT, Quan TE, Rudenga BJ, Roman RM, Craft J, et al. Transfer of antigen from human B cells to dendritic cells. Mol Immunol (2014) 58(1):56-65. doi:10.1016/j.molimm.2013.10.013
56. Rodriguez-Pinto D, Saravia NG, McMahon-Pratt D. CD4 T cell activation by B cells in human Leishmania (Viannia) infection. BMC Infect Dis (2014) 14:108. doi:10.1186/1471-2334-14-108
57. Pancari G, Fan H, Smith S, Joshi A, Haimbach R, Clark D, et al. Characterization of the mechanism of protection mediated by CS-D7, a monoclonal antibody to Staphylococcus aureus iron regulated surface determinant B (IsdB). Front Cell Infect Microbiol (2012) 2:36. doi:10.3389/fcimb.2012.00036
58. Lambris JD, Ricklin D, Geisbrecht BV. Complement evasion by human pathogens. Nat Rev Microbiol (2008) 6(2):132-42. doi:10.1038/nrmicro1824
59. Gasque P. Complement: a unique innate immune sensor for danger signals. Mol Immunol (2004) 41(11):1089-98. doi:10.1016/j.molimm.2004.06.011
60. Quilty S, Kwok G, Hajkowicz K, Currie B. High incidence of methicillin-resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Intern Med J (2009) 39(8):557-9. doi:10.1111/j.1445-5994.2009.02003.x
61. Swati M, Gita N, Sujata B, Farah J, Preeti M. Microbial etiology of febrile neutropenia. Indian J Hematol Blood Transfus (2010) 26(2):49-55. doi:10.1007/s12288-010-0029-z
62. Morris PG, Hassan T, McNamara M, Hassan A, Wiig R, Grogan L, et al. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia - a cause for concern. Support Care Cancer (2008) 16(9):1085-8. doi:10.1007/s00520-007-0398-5
63. Shaw BE, Boswell T, Byrne JL, Yates C, Russell NH. Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. Bone Marrow Transplant (2007) 39(10):623-9. doi:10.1038/sj.bmt.1705654
64. Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol (2014) 175(2):139-49. doi:10.1111/cei.12202
65. Song E, Jaishankar GB, Saleh H, Jithpratuck W, Sahni R, Krishnaswamy G. Chronic granulomatous disease: a review of the infectious and inflammatory complications. Clin Mol Allergy (2011) 9(1):10. doi:10.1186/1476-7961-9-10
66. Holland SM, DeLeo FR, Elloumi HZ, Hsu AP, Uzel G, Brodsky N, et al. STAT3 mutations in the hyper-IgE syndrome. N Engl J Med (2007) 357(16):1608-19. doi:10.1056/NEJMoa073687
67. White CJ, Gallin JI. Phagocyte defects. Clin Immunol Immunopathol (1986) 40(1):50-61. doi:10.1016/0090-1229(86)90068-1
68. Badolato R. Defects of leukocyte migration in primary immunodeficiencies. Eur J Immunol (2013) 43(6):1436-40. doi:10.1002/eji.201243155
69. Schmidt S, Moser M, Sperandio M. The molecular basis of leukocyte recruitment and its deficiencies. Mol Immunol (2013) 55(1):49-58. doi:10.1016/j.molimm.2012.11.006
70. Greenlee-Wacker MC, Rigby KM, Kobayashi SD, Porter AR, DeLeo FR, Nauseef WM. Phagocytosis of Staphylococcus aureus by human neutrophils prevents macrophage efferocytosis and induces programmed necrosis. J Immunol (2014) 192(10):4709-17. doi:10.4049/jimmunol.1302692
71. Schindler D, Gutierrez MG, Beineke A, Rauter Y, Rohde M, Foster S, et al. Dendritic cells are central coordinators of the host immune response to Staphylococcus aureus bloodstream infection. Am J Pathol (2012) 181(4):1327-37. doi:10.1016/j.ajpath.2012.06.039
72. Sun K, Metzger DW. Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection. J Immunol (2014) 192(7):3301-7. doi:10.4049/jimmunol.1303049
73. Doisne JM, Tan TC, Colucci F. Guardian of the genome turns on genes that alert natural killer cells. Cell Cycle (2011) 10(22):3822-3. doi:10.4161/cc.10.22.18196
74. Wallemacq H, Bedoret D, Pujol J, Desmet C, Drion PV, Farnir F, et al. CD40 triggering induces strong cytotoxic T lymphocyte responses to heat-killed Staphylococcus aureus immunization in mice: a new vaccine strategy for staphylococcal mastitis. Vaccine (2012) 30(12):2116-24. doi:10.1016/j.vaccine.2012.01.039
75. van Belkum A, Melles DC, Nouwen J, van Leeuwen WB, van Wamel W, Vos MC, et al. Co-evolutionary aspects of human colonisation and infection by Staphylococcus aureus. Infect Genet Evol (2009) 9(1):32-47. doi:10.1016/j.meegid.2008.09.012
76. van Gils EJ, Hak E, Veenhoven RH, Rodenburg GD, Bogaert D, Bruin JP, et al. Effect of seven-valent pneumococcal conjugate vaccine on Staphylococcus aureus colonisation in a randomised controlled trial. PLoS One (2011) 6(6):e20229. doi:10.1371/journal.pone.0020229
77. Mina MJ, McCullers JA, Klugman KP. Live attenuated influenza vaccine enhances colonization of Streptococcus pneumoniae and Staphylococcus aureus in mice. MBio (2014) 5(1):e1040-1013. doi:10.1128/mBio.01040-13
78. Eloe-Fadrosh EA, McArthur MA, Seekatz AM, Drabek EF, Rasko DA, Sztein MB, et al. Impact of oral typhoid vaccination on the human gut microbiota and correlations with S. typhi-specific immunological responses. PLoS One (2013) 8(4):e62026. doi:10.1371/journal.pone.0062026
79. Ferreira RB, Antunes LC, Finlay BB. Should the human microbiome be considered when developing vaccines? PLoS Pathog (2010) 6(11):e1001190. doi:10.1371/journal.ppat.1001190
80. Baquir B, Lin L, Ibrahim AS, Fu Y, Avanesian V, Tu A, et al. Immunological reactivity of blood from healthy humans to the rAls3p-N vaccine protein. J Infect Dis (2010) 201(3):473-7. doi:10.1086/649901
81. Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, et al. NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine (2012) 30(52):7594-600. doi:10.1016/j.vaccine.2012.10.038
82. Harro CD, Betts RF, Hartzel JS, Onorato MT, Lipka J, Smugar SS, et al. The immunogenicity and safety of different formulations of a novel Staphylococcus aureus vaccine (V710): results of two phase I studies. Vaccine (2012) 30(9):1729-36. doi:10.1016/j.vaccine.2011.12.045
83. Ibarz-Pavón AB, Maclennan J, Andrews NJ, Gray SJ, Urwin R, Clarke SC, et al. Changes in serogroup and genotype prevalence among carried meningococci in the United Kingdom during vaccine implementation. J Infect Dis (2011) 204(7):1046-53. doi:10.1093/infdis/jir466
84. Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med (2013) 10(9):e1001517. doi:10.1371/journal.pmed.1001517
85. Shirtliff ME, Peters BM, Jabra-Rizk MA. Cross-kingdom interactions: Candida albicans and bacteria. FEMS Microbiol Lett (2009) 299(1):1-8. doi:10.1111/j.1574-6968.2009.01668.x
86. Chotirmall SH, O'Donoghue E, Bennett K, Gunaratnam C, O'Neill SJ, McElvaney NG. Sputum Candida albicans presages FEV(1) decline and hospital-treated exacerbations in cystic fibrosis. Chest (2010) 138(5):1186-95. doi:10.1378/chest.09-2996
87. Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D, et al. Adaptation of Pseudomonas aeruginosa in cystic fibrosis airways influences virulence of Staphylococcus aureus in vitro and murine models of co-infection. PLoS One (2014) 9(3):e89614. doi:10.1371/journal.pone.0089614
88. Shinefield H, Black S, Fattom A, Horwith G, Rasgon S, Ordonez J, et al. Use of a Staphylococcus aureus conjugate vaccine in patients receiving hemodialysis. N Engl J Med (2002) 346(7):491-6. doi:10.1056/NEJMoa011297
89. Fowler VG, Allen KB, Moreira ED, Moustafa M, Isgro F, Boucher HW, et al. Effect of an investigational vaccine for preventing Staphylococcus aureus infections after cardiothoracic surgery: a randomized trial. JAMA (2013) 309(13):1368-78. doi:10.1001/jama.2013.3010
90. Boles JW, Pitt ML, LeClaire RD, Gibbs PH, Torres E, Dyas B, et al. Generation of protective immunity by inactivated recombinant staphylococcal enterotoxin B vaccine in nonhuman primates and identification of correlates of immunity. Clin Immunol (2003) 108(1):51-9. doi:10.1016/S1521-6616(03)00066-4
91. Stiles BG, Garza AR, Ulrich RG, Boles JW. Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model. Infect Immun (2001) 69(4):2031-6. doi:10.1128/IAI.69.4.2031-2036.2001
92. Anderson AS, Miller AA, Donald RG, Scully IL, Nanra JS, Cooper D, et al. Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors. Hum Vaccin Immunother (2012) 8(11):1585-94. doi:10.4161/hv.21872
93. Fattom AI, Horwith G, Fuller S, Propst M, Naso R. Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials. Vaccine (2004) 22(7):880-7. doi:10.1016/j.vaccine.2003.11.034
94. O'Brien CN, Guidry AJ, Fattom A, Shepherd S, Douglass LW, Westhoff DC. Production of antibodies to Staphylococcus aureus serotypes 5, 8, and 336 using poly(DL-lactide-co-glycolide) microspheres. J Dairy Sci (2000) 83(8):1758-66. doi:10.3168/jds.S0022-0302(00)75046-6
95. Zecconi A, Scali F. Staphylococcus aureus virulence factors in evasion from innate immune defenses in human and animal diseases. Immunol Lett (2013) 150(1-2):12-22. doi:10.1016/j.imlet.2013.01.004
96. Kraus D, Peschel A. Staphylococcus aureus evasion of innate antimicrobial defense. Future Microbiol (2008) 3(4):437-51. doi:10.2217/17460913.3.4.437
97. Rigby KM, DeLeo FR. Neutrophils in innate host defense against Staphylococcus aureus infections. Semin Immunopathol (2012) 34(2):237-59. doi:10.1007/s00281-011-0295-3
98. Skurnik D, Kropec A, Roux D, Theilacker C, Huebner J, Pier GB. Natural antibodies in normal human serum inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis (2012) 55(9):1188-97. doi:10.1093/cid/cis624
99. Ehrhardt GR, Hijikata A, Kitamura H, Ohara O, Wang JY, Cooper MD. Discriminating gene expression profiles of memory B cell subpopulations. J Exp Med (2008) 205(8):1807-17. doi:10.1084/jem.20072682
100. Kobrynski LJ, Tanimune L, Kilpatrick L, Campbell DE, Douglas SD. Production of T-helper cell subsets and cytokines by lymphocytes from patients with chronic mucocutaneous candidiasis. Clin Diagn Lab Immunol (1996) 3(6):740-5.
101. Turner DL, Gordon CL, Farber DL. Tissue-resident T cells, in situ immunity and transplantation. Immunol Rev (2014) 258(1):150-66. doi:10.1111/imr.12149
102. Fowler VG Jr, Proctor RA. Where does a Staphylococcus aureus vaccine stand? Clin Microbiol Infect (2014) 20(Suppl 5):66-75. doi:10.1111/1469-0691.12570
103. Schreiner J, Kretschmer D, Klenk J, Otto M, Bühring HJ, Stevanovic S, et al. Staphylococcus aureus phenol-soluble modulin peptides modulate dendritic cell functions and increase in vitro priming of regulatory T cells. J Immunol (2013) 190(7):3417-26. doi:10.4049/jimmunol.1202563
104. Ardura MI, Banchereau R, Mejias A, Di Pucchio T, Glaser C, Allantaz F, et al. Enhanced monocyte response and decreased central memory T cells in children with invasive Staphylococcus aureus infections. PLoS One (2009) 4(5):e5446. doi:10.1371/journal.pone.0005446
105. Rabe H, Nordström I, Andersson K, Lundell AC, Rudin A. Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis. Immunology (2014) 141(3):467-81. doi:10.1111/imm.12209
106. Chen Z, Han Y, Gu Y, Liu Y, Jiang Z, Zhang M, et al. CD11c(high)CD8+ regulatory T cell feedback inhibits CD4 T cell immune response via Fas ligand-Fas pathway. J Immunol (2013) 190(12):6145-54. doi:10.4049/jimmunol.1300060
107. Farkas T, Thornton SA, Wilton N, Zhong W, Altaye M, Jiang X. Homologous versus heterologous immune responses to Norwalk-like viruses among crew members after acute gastroenteritis outbreaks on 2 US Navy vessels. J Infect Dis (2003) 187(2):187-93. doi:10.1086/367809
108. Díaz I, Gimeno M, Darwich L, Navarro N, Kuzemtseva L, López S, et al. Characterization of homologous and heterologous adaptive immune responses in porcine reproductive and respiratory syndrome virus infection. Vet Res (2012) 43:30. doi:10.1186/1297-9716-43-30
109. Nabel GJ, Fauci AS. Induction of unnatural immunity: prospects for a broadly protective universal influenza vaccine. Nat Med (2010) 16(12):1389-91. doi:10.1038/nm1210-1389
110. Casadevall A, Pirofski LA. Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol (2003) 24(9):474-8. doi:10.1016/S1471-4906(03)00228-X
111. DeJonge M, Burchfield D, Bloom B, Duenas M, Walker W, Polak M, et al. Clinical trial of safety and efficacy of INH-A21 for the prevention of nosocomial staphylococcal bloodstream infection in premature infants. J Pediatr (2007) 151(3):260-5, 265.e1. doi:10.1016/j.jpeds.2007.04.060
112. Burnside K, Lembo A, Harrell MI, Klein JA, Lopez-Guisa J, Siegesmund AM, et al. Vaccination with a UV-irradiated genetically attenuated mutant of Staphylococcus aureus provides protection against subsequent systemic infection. J Infect Dis (2012) 206(11):1734-44. doi:10.1093/infdis/jis579
113. Hua L, Hilliard JJ, Shi Y, Tkaczyk C, Cheng LI, Yu X, et al. Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumonia. Antimicrob Agents Chemother (2014) 58(2):1108-17. doi:10.1128/AAC.02190-13
114. Ragle BE, Bubeck Wardenburg J. Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun (2009) 77(7):2712-8. doi:10.1128/IAI.00115-09
115. Mocca CP, Brady RA, Burns DL. Role of antibodies in protection elicited by active vaccination with genetically inactivated alpha hemolysin in a mouse model of Staphylococcus aureus skin and soft tissue infections. Clin Vaccine Immunol (2014) 21(5):622-7. doi:10.1128/CVI.00051-14
116. Yoong P, Pier GB. Antibody-mediated enhancement of community-acquired methicillin-resistant Staphylococcus aureus infection. Proc Natl Acad Sci U S A (2010) 107(5):2241-6. doi:10.1073/pnas.0910344107
117. Weems JJ Jr, Steinberg JP, Filler S, Baddley JW, Corey GR, Sampathkumar P, et al. Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2006) 50(8):2751-5. doi:10.1128/AAC.00096-06
118. Proctor RA. Challenges for a universal Staphylococcus aureus vaccine. Clin Infect Dis (2012) 54(8):1179-86. doi:10.1093/cid/cis033
119. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A (2013) 110(9):3507-12. doi:10.1073/pnas.1222878110
120. Kim HK, Missiakas D, Schneewind O. Mouse models for infectious diseases caused by Staphylococcus aureus. J Immunol Methods (2014) 410:88-99. doi:10.1016/j.jim.2014.04.007
121. Sung JM, Lloyd DH, Lindsay JA. Staphylococcus aureus host specificity: comparative genomics of human versus animal isolates by multi-strain microarray. Microbiology (2008) 154(Pt 7):1949-59. doi:10.1099/mic.0.2007/015289-0
122. Jansen KU, Girgenti DQ, Scully IL, Anderson AS. Vaccine review: "Staphylococcus aureus vaccines: problems and prospects". Vaccine (2013) 31(25):2723-30. doi:10.1016/j.vaccine.2013.04.002
123. Ahn SH, Tsalik EL, Cyr DD, Zhang Y, van Velkinburgh JC, Langley RJ, et al. Gene expression-based classifiers identify Staphylococcus aureus infection in mice and humans. PLoS One (2013) 8(1):e48979. doi:10.1371/journal.pone.0048979
124. Date SV, Modrusan Z, Lawrence M, Morisaki JH, Toy K, Shah IM, et al. Global gene expression of methicillin-resistant Staphylococcus aureus USA300 during human and mouse infection. J Infect Dis (2014) 209(10):1542-50. doi:10.1093/infdis/jit668
125. Casadevall A, Pirofski LA. Exploiting the redundancy in the immune system: vaccines can mediate protection by eliciting "unnatural" immunity. J Exp Med (2003) 197(11):1401-4. doi:10.1084/jem.20030637
126. Jenner E. On Vaccination Against Smallpox: An Inquiry into the Causes and Effects of the Variole Vaccine, or Cow Pox. London: Sampson Low (1798).
127. Murphy SG. Tetanus toxin and antigenic derivatives. II. Effect of protein and formaldehyde concentration on toxoid formation. J Bacteriol (1967) 94(3):586-9.
128. Novitsky V, Smith UR, Gilbert P, McLane MF, Chigwedere P, Williamson C, et al. Human immunodeficiency virus type 1 subtype C molecular phylogeny: consensus sequence for an AIDS vaccine design? J Virol (2002) 76(11):5435-51. doi:10.1128/JVI.76.11.5435-5451.2002
129. Koita OA, Dabitao D, Mahamadou I, Tall M, Dao S, Tounkara A, et al. Confirmation of immunogenic consensus sequence HIV-1 T-cell epitopes in Bamako, Mali and Providence, Rhode Island. Hum Vaccin (2006) 2(3):119-28. doi:10.4161/hv.2869
130. Giles BM, Ross TM. A computationally optimized broadly reactive antigen (COBRA) based H5N1 VLP vaccine elicits broadly reactive antibodies in mice and ferrets. Vaccine (2011) 29(16):3043-54. doi:10.1016/j.vaccine.2011.01.100
131. Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr (2010) 10:4. doi:10.1186/1471-2431-10-4
132. McNeely TB, Staub JM, Rusk CM, Blum MJ, Donnelly JJ. Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques. Infect Immun (1998) 66(8):3705-10.
133. Jakobsen H, Sigurdsson VD, Sigurdardottir S, Schulz D, Jonsdottir I. Pneumococcal serotype 19F conjugate vaccine induces cross-protective immunity to serotype 19A in a murine pneumococcal pneumonia model. Infect Immun (2003) 71(5):2956-9. doi:10.1128/IAI.71.5.2956-2959.2003
134. Richter SS, Heilmann KP, Dohrn CL, Riahi F, Diekema DJ, Doern GV. Pneumococcal serotypes before and after introduction of conjugate vaccines, United States, 1999-2011(1.). Emerg Infect Dis (2013) 19(7):1074-83. doi:10.3201/eid1907.121830
135. Hulten KG, Kaplan SL, Lamberth LB, Barson WJ, Romero JR, Lin PL, et al. Changes in Streptococcus pneumoniae serotype 19A invasive infections in children from 1993 to 2011. J Clin Microbiol (2013) 51(4):1294-7. doi:10.1128/JCM.00058-13
136. Dudas RA, Karron RA. Respiratory syncytial virus vaccines. Clin Microbiol Rev (1998) 11(3):430-9.
137. Fu Y, Ibrahim AS, Sheppard DC, Chen YC, French SW, Cutler JE, et al. Candida albicans Als1p: an adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol (2002) 44:61-72. doi:10.1046/j.1365-2958.2002.02873.x
138. Phan QT, Myers CL, Fu Y, Sheppard DC, Yeaman MR, Welch WH, et al. Als3 is a Candida albicans invasin that binds to cadherins and induces endocytosis by host cells. PLoS Biol (2007) 5(3):e64. doi:10.1371/journal.pbio.0050064
139. Sheppard DC, Yeaman MR, Welch WH, Phan QT, Fu Y, Ibrahim AS, et al. Functional and structural diversity in the Als protein family of Candida albicans. J Biol Chem (2004) 279:30480-9. doi:10.1074/jbc.M401929200
140. Lin L, Ibrahim AS, Xu X, Farber JM, Avanesian V, Baquir B, et al. Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog (2009) 5(12):e1000703. doi:10.1371/journal.ppat.1000703
141. Yeaman MR, Filler SG, Schmidt CS, Chaili S, Barr K, Wang H, et al. Efficacy and immunologic mechanisms of NDV-3 vaccine in a murine model of MRSA skin/skin structure infection. 52nd ICAAC. San Francisco, CA (2012). Abstract No. G-868.
142. Festa M, Brun P, Piccinini R, Castagliuolo I, Basso B, Zecconi A. Staphylococcus aureus Efb protein expression in Nicotiana tabacum and immune response to oral administration. Res Vet Sci (2013) 94(3):484-9. doi:10.1016/j.rvsc.2012.10.012
143. Camussone CM, Veaute CM, Pujato N, Morein B, Marcipar IS, Calvinho LF. Immune response of heifers against a Staphylococcus aureus CP5 whole cell and lysate vaccine formulated with ISCOM matrix adjuvant. Res Vet Sci (2014) 96(1):86-94. doi:10.1016/j.rvsc.2013.10.004
144. Camussone CM, Veaute CM, Porporatto C, Morein B, Marcipar IS, Calvinho LF. Immune response of heifers against a Staphylococcus aureus CP5 whole cell vaccine formulated with ISCOMATRIX adjuvant. J Dairy Res (2013) 80(1):72-80. doi:10.1017/S0022029912000593
145. Luo G, Hennessey JP Jr, Schmidt CS, Fu Y, Yeaman MR, Filler SG, et al. Human vaccination with rAls3p-N produces antibodies that enhance phagocyte-mediated killing of C. albicans and S. aureus and mitigate Als3p functions. 18th Congress of the International Society for Human and Animal Mycology. Berlin (2012).
146. Klotz SA, Chasin BS, Powell B, Gaur NK, Lipke PN. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis (2007) 59(4):401-6. doi:10.1016/j.diagmicrobio.2007.07.001
147. Spellberg BJ, Ibrahim AS, Avanesian V, Fu Y, Myers C, Phan QT, et al. Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis (2006) 194(2):256-60. doi:10.1086/504691
148. Ibrahim AS, Luo G, Gebremariam T, Lee H, Schmidt CS, Hennessey JP Jr, et al. NDV-3 protects mice from vulvovaginal candidiasis through T- and B-cell immune response. Vaccine (2013) 31(47):5549-56. doi:10.1016/j.vaccine.2013.09.016
149. Bär E, Gladiator A, Bastidas S, Roschitzki B, Acha-Orbea H, Oxenius A, et al. A novel Th cell epitope of Candida albicans mediates protection from fungal infection. J Immunol (2012) 188(11):5636-43. doi:10.4049/jimmunol.1200594
150. Pentier JM, Sewell AK, Miles JJ. Advances in T-cell epitope engineering. Front Immunol (2013) 4:133. doi:10.3389/fimmu.2013.00133
151. McNeil SA, Halperin SA, Langley JM, Smith B, Warren A, Sharratt GP, et al. Safety and immunogenicity of 26-valent group a Streptococcus vaccine in healthy adult volunteers. Clin Infect Dis (2005) 41(8):1114-22. doi:10.1086/444458
152. Zeng W, Horrocks KJ, Robevska G, Wong CY, Azzopardi K, Tauschek M, et al. A modular approach to assembly of totally synthetic self-adjuvanting lipopeptide-based vaccines allows conformational epitope building. J Biol Chem (2011) 286(15):12944-51. doi:10.1074/jbc.M111.227744
153. Sahdev P, Ochyl LJ, Moon JJ. Biomaterials for nanoparticle vaccine delivery systems. Pharm Res (2014). doi:10.1007/s11095-014-1419-y
154. Gregory AE, Titball R, Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol (2013) 3:13. doi:10.3389/fcimb.2013.00013
155. Lambrecht BN, Hammad H. Biology of lung dendritic cells at the origin of asthma. Immunity (2009) 31(3):412-24. doi:10.1016/j.immuni.2009.08.008
156. Vander Lugt B, Khan AA, Hackney JA, Agrawal S, Lesch J, Zhou M, et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat Immunol (2014) 15(2):161-7. doi:10.1038/ni.2795
157. Cruz LJ, Rueda F, Simón L, Cordobilla B, Albericio F, Domingo JC. Liposomes containing NYESO1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines. Nanomedicine (Lond) (2014) 9(4):435-49. doi:10.2217/NNM.13.66
158. Kaslow DC, Shiver JW. Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development. Annu Rev Med (2011) 62:201-15. doi:10.1146/annurev-med-051109-101544
159. Proctor RA. Is there a future for a Staphylococcus aureus vaccine? Vaccine (2012) 30(19):2921-7. doi:10.1016/j.vaccine.2011.11.006